Chugai Pharmaceutical Co., Ltd. (FRA:CUP)

Germany flag Germany · Delayed Price · Currency is EUR
44.20
-1.50 (-3.28%)
Last updated: Dec 1, 2025, 9:59 AM CET
12.81%
Market Cap73.59B
Revenue (ttm)6.99B
Net Income (ttm)2.29B
Shares Outn/a
EPS (ttm)1.39
PE Ratio32.17
Forward PEn/a
Dividend1.09 (2.38%)
Ex-Dividend DateJun 27, 2025
Volumen/a
Average Volume30
Open44.22
Previous Close45.70
Day's Range44.20 - 44.22
52-Week Range33.02 - 53.18
Betan/a
RSI53.23
Earnings DateJan 29, 2026

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 re... [Read more]

Industry Pharmaceutical Preparations
Founded 1925
Employees 5,026
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol CUP
Full Company Profile

Financial Performance

In 2024, Chugai Pharmaceutical's revenue was 1.17 trillion, an increase of 5.33% compared to the previous year's 1.11 trillion. Earnings were 387.32 billion, an increase of 19.00%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.